Mustang Bio Posts Encouraging Interim Data From Gene Therapy Trial In Immunodeficiency
Mustang Bio Inc (NASDAQ:MBIO) announced interim data from the Phase 1/2 trial of MB-107, lentiviral gene therapy for X-linked severe combined…
Mustang Bio Highlights Data On Treatment With Lentiviral Viral Vector Gene Therapy For X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation At American Society Of Gene & Cell Therapy Meeting May 19
Data represent largest cohort of infants with XSCID, also known as bubble boy disease, who received lentiviral gene therapy with the longest follow-up to date
Seventeen of 18 patients with follow-up greater than 6
63 Biggest Movers From Yesterday
Gainers
InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
